GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » The Joint Corp (NAS:JYNT) » Definitions » ROE %

The Joint (The Joint) ROE % : -147.21% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is The Joint ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. The Joint's annualized net income for the quarter that ended in Dec. 2023 was $-44.2 Mil. The Joint's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $30.0 Mil. Therefore, The Joint's annualized ROE % for the quarter that ended in Dec. 2023 was -147.21%.

The historical rank and industry rank for The Joint's ROE % or its related term are showing as below:

JYNT' s ROE % Range Over the Past 10 Years
Min: -109.94   Med: -16.02   Max: 103.1
Current: -29.9

During the past 12 years, The Joint's highest ROE % was 103.10%. The lowest was -109.94%. And the median was -16.02%.

JYNT's ROE % is ranked worse than
80.66% of 610 companies
in the Healthcare Providers & Services industry
Industry Median: 4.115 vs JYNT: -29.90

The Joint ROE % Historical Data

The historical data trend for The Joint's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Joint ROE % Chart

The Joint Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 103.10 98.09 29.43 2.00 -34.03

The Joint Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.53 27.51 -3.63 -8.10 -147.21

Competitive Comparison of The Joint's ROE %

For the Medical Care Facilities subindustry, The Joint's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


The Joint's ROE % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, The Joint's ROE % distribution charts can be found below:

* The bar in red indicates where The Joint's ROE % falls into.



The Joint ROE % Calculation

The Joint's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-9.752/( (32.563+24.747)/ 2 )
=-9.752/28.655
=-34.03 %

The Joint's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-44.168/( (35.26+24.747)/ 2 )
=-44.168/30.0035
=-147.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


The Joint  (NAS:JYNT) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-44.168/30.0035
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-44.168 / 122.456)*(122.456 / 92.862)*(92.862 / 30.0035)
=Net Margin %*Asset Turnover*Equity Multiplier
=-36.07 %*1.3187*3.095
=ROA %*Equity Multiplier
=-47.57 %*3.095
=-147.21 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-44.168/30.0035
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-44.168 / -0.576) * (-0.576 / 5.48) * (5.48 / 122.456) * (122.456 / 92.862) * (92.862 / 30.0035)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 76.6806 * -0.1051 * 4.48 % * 1.3187 * 3.095
=-147.21 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


The Joint ROE % Related Terms

Thank you for viewing the detailed overview of The Joint's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


The Joint (The Joint) Business Description

Traded in Other Exchanges
N/A
Address
16767 North Perimeter Drive, Suite 110, Scottsdale, AZ, USA, 85260
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sale of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has two operating business segments; the Corporate Clinics segment is comprised of the operating activities of the company-owned or managed clinics, and The Franchise Operations segment is comprised of the operating activities of the franchise business unit. The company generates maximum revenue from the Corporate clinic's segment.
Executives
Bandera Partners Llc 10 percent owner 50 BROAD STREET, SUITE 1820, NEW YORK NY 10004
Peter D Holt officer: Chief Operating Officer 16767 N. PERIMETER DR., SUITE 240, SCOTTSDALE AZ 85260
Jake Singleton officer: Chief Financial Officer 16767 NORTH PERIMETER DRIVE, SUITE 240, SCOTTSDALE AZ 85260
Ronald V Davella director 2600 E SOUTHLAKE BLVD., STE 120-359, SOUTHLAKE TX 76092
Glenn J Krevlin 10 percent owner 600 FIFTH AVE, 11TH FL, NEW YORK NY 10020
Matthew E Rubel director 3231 SE SIXTH AVENUE, TOPEKA KS 66607
Gregory Bylinsky 10 percent owner C/O BANDERA PARTNERS LLC, 50 BROAD STREET, SUITE 1820, NEW YORK NY 10004
Jefferson Gramm 10 percent owner C/O BANDERA PARTNERS LLC, 50 BROAD STREET, SUITE 1820, NEW YORK NY 10004
Amos James H. Jr director 16767 N. PERIMETER DR., STE. 240, SCOTTSDALE AZ 85260
John P Meloun officer: Chief Financial Officer 16767 N. PERIMETER DR., STE. 240, SCOTTSDALE AZ 85260
Abe Hong director 16767 NORTH PERIMETER DRIVE, SUITE 240, SCOTTSDALE AZ 85260
Glenhill Advisors Llc 10 percent owner 600 FIFTH AVE, 11TH FL, NEW YORK NY 10020
Suzanne M Decker director 16767 NORTH PERIMETER DRIVE, SUITE 240, SCOTTSDALE AZ 85260
Bret Sanders director 16767 N. PERIMETER DR., STE. 240, SCOTTSDALE AZ 85260
David M Orwasher officer: President and COO 242 W 36TH ST, NEW YORK NY 10018